Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Meletios A Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet‐Loiseau, Saad Z. Usmani
Michael Wang, Meletios A Dimopoulos, Christine Chen, María Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Donna M. Weber
Sagar Lonial, Meletios A Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesús F. San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt,
Discussion(0)
No comments yet. Be the first to comment.